Trials / Completed
CompletedNCT01462149
Efficacy Study of Neoadjuvant Chemotherapy to Treat Advanced Ovarian Cancer
Phase II Trial of Docetaxel and Carboplatin as Neoadjuvant Chemotherapy in Patients With Advanced Ovarian Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 43 (actual)
- Sponsor
- Asan Medical Center · Academic / Other
- Sex
- Female
- Age
- 20 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
Neoadjuvant chemotherapy is alternative treatment option to upfront cytoreductive surgery to treat advanced ovarian cancer. Paclitaxel plus carboplatin is most frequently selected chemotherapeutic regimen for neoadjuvant chemotherapy. Docetaxel had similar therapeutic efficacy compared to paclitaxel in adjuvant chemotherapy trials in ovarian cancer. However, docetaxel had more favorable toxicity profile. Therefore, the investigators aimed to evaluate the efficacy of docetaxel plus carboplatin as neoadjuvant chemotherapy in patients with advanced ovarian cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Neoadjuvant chemotherapy | Docetaxel 75mg/m2BAS, q 3 weeks, 3 cycles |
| DRUG | Carboplatin | Carboplatin AUC 5, q 3 weeks, 3 cycles |
Timeline
- Start date
- 2011-10-01
- Primary completion
- 2016-06-01
- Completion
- 2016-06-01
- First posted
- 2011-10-31
- Last updated
- 2017-05-31
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT01462149. Inclusion in this directory is not an endorsement.